What happened
Orient Bio updated its previously filed separate results for the fiscal year ended Mar 2026: revenue of US$19.4M (+1.2% year on year), an operating loss of US$2.69M and a net loss of US$2.97M.
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$19.4M |
|---|---|
| Revenue vs a year earlier | +1.2% |
| Operating profit | −US$2.69M |
| Net income | −US$2.97M |
| Period | the fiscal year ended Mar 2026 (separate) |
| Filed | 2026-06-19, [Amended] Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260619801030 → open original filing |
Versions of this filing
- 2026-05-15Original
- 2026-06-19Amendment 1 (this page)
Source: DART. Information only, not investment advice.